nyuuzyou/wikis huggingface dataset:
Anakinra (Kineret)

Recombinant IL-1 receptor antagonist
==Diseases for which it is used==
*Castleman disease
==Also known as==
*Brand name: Kineret
Category:Drugs
Category:Subcutaneous medications
Category:IL-1R antagonists
Category:Recombinant medications
Category:Castleman disease medications
Category:FDA approved in 2001
Category:Stub
Anastrozole (Arimidex)

==General information==
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues.Anastrozole (Arimidex) package insert Anastrozole (Arimidex) package insert (locally hosted backup)Arimidex manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Breast cancer
*Endometrial cancer
==Patient drug information==
*Anastrozole (Arimidex) package insert
*Anastrozole (Arimidex) patient drug information (Chemocare)Anastrozole (Arimidex) patient drug information (Chemocare)
*Anastrozole (Arimidex) patient drug information (UpToDate)Anastrozole (Arimidex) patient drug information (UpToDate)
==History of changes in FDA indication==
*1995-12-27: Initial approval for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. (Based on Buzdar et al. 1996 & Jonat et al. 1996)
*2002-09-05: Accelerated approval for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. (Based on ATAC)
**2005-09-16: Converted to regular approval for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. (Based on ATAC)
*Uncertain date: Approved for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. (Based on Arimidex Study Group 2000 & TARGETBreast)
==History of changes in EMA indication==
The approval of this drug pre-dates the EMA.
*1995-08-11: EURD
==History of changes in Health Canada indication==
*2004-06-30: Initial notice of compliance with conditions
*2008-12-02: Conditions were met
==Also known as==
*Brand names: Altraz, Anabrez, Anastraze, Anastrazol Rontag, Anastrol, Arimidex, Asiolex, Karomex, Leprofen, RUI SI YI, RUI Ting, Trozolet, Trozolite.
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:Aromatase inhibitors, third generation
Category:Breast cancer medications
Category:Endometrial cancer medications
Category:FDA approved in 1995
Category:EMA approved in 1995
Category:Health Canada approved in 2004
Category:WHO Essential Cancer Medicine
Ancestim (Stemgen)

Recombinant human stem cell factor
==Also known as==
*Brand name: Stemgen
== Patient Drug Information==
*Ancestim (Stemgen) Drug MonographAncestim (Stemgen) Drug Monograph
==References==
 
Category:Drugs
Category:Recombinant medications
Category:Subcutaneous medications
Category:FDA approved in 2009
Category:Stub
Andexanet alfa (Andexxa)

==General information==
Class/mechanism: Recombinant inactive FXa, used for specific reversal of DOACs (direct oral anticoagulants) Rivaroxaban (Xarelto) and Apixaban (Eliquis). Coagulation factor Xa (recombinant) inactivated-zheo binds and sequesters rivaroxaban and apixaban, negating their factor Xa inhibiting, anticoagulant effect. It also inhibits Tissue Factor Pathway Inhibitor (TFPI); inhibition of TFPI can increase tissue factor-initiated thrombin generation.Factor Xa, recombinant, inactivated-zhzo (Andexxa) package insert Factor Xa, recombinant, inactivated-zhzo (Andexxa) package insert (locally hosted backup)Andexxa manufacturer's website
Route: IV
Extravasation: no information
*IUPHAR/BPS
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Factor Xa, recombinant, inactivated-zhzo (Andexxa) package insert
==Diseases for which it is used==
*Bleeding with anticoagulation
==History of changes in FDA indication==
*2018-05-04: Approved for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is necessary due to fatal or uncontrolled bleeding.
==History of changes in PMDA indication==
*2022-03-28: Newly indicated for the reversal of anticoagulant effect in life-threatening or uncontrolled bleeding in patients treated with a direct-acting factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban tosilate hydrate).
=Also known as=
*Code name: PRT-4445
*Generic name: coagulation factor Xa recombinant inactivated-zhzo
*Brand name: Andexxa, Ondexxya
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Hemostasis medications
Category:Recombinant medications
Category:FDA approved in 2018
Category:EMA approved in 2019
Category:PMDA approved in 2022
Anemia

*We have moved How I Treat articles to a dedicated page.
=Guidelines=
==NCCN==
*NCCN Guidelines - Cancer- and Chemotherapy-Induced Anemia
**2012: Rodgers et al. Cancer- and chemotherapy-induced anemia. EuroPMC
**2008: Rodgers et al. Cancer- and chemotherapy-induced anemia. EuroPMC
**2003: Sabbatini et al. Anemia clinical practice guidelines in oncology. EuroPMC
=Initial evaluation=
May consist of:
*CBC with differential, MCV
*Basic metabolic panel (BMP)
*Liver function tests (LFTs)
*Reticulocyte count
*Iron, total iron binding capacity (TIBC), ferritin
*Vitamin B12 +/- methylmalonic acid & homocysteine
*Folic acid
*TSH
*Peripheral smear
*Clinical history, lifestyle factors (e.g. alcohol)
*Medications
===GI bleeding or iron deficiency===
*Stool occult blood
*EGD & colonoscopy
*Celiac (TTG IgA)
*H. pylori Ab, H. pylori stool antigen
===Hemolysis?===
*LDH
*Haptoglobin
*Direct & indirect Coombs
*LFTs (direct, indirect, total bilirubin)
*Infectious: anaplasma, babesia, ehrlichia
===Anemia of chronic disease/anemia chronic kidney disease===
*Basic metabolic panel (BMP) & iron labs as above
*Serum erythropoietin
*ESR
*CRP
===Chronic/inherited?===
*Hemoglobin electrophoresis
*Sickle cell evaluation
===Myeloma?===
*SPEP & IFE
*UPEP
*Free serum/urine kappa/lambda light chains
*Skeletal survey
===Primary marrow process/hematologic malignancy===
*Bone marrow biopsy
===Less common===
*Copper
*Zinc
Category:Hematology reference pages
Anlotinib (Fukewei)

==Mechanism of action==
From the NCI Drug Dictionary: The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
*IUPHAR/BPS
==Diseases for which it is used==
*Non-small cell lung cancer
==History of changes in NMPA indication==
*2018-05-08: Approved as a treatment for patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy. (Based on ALTER 0303)
==Also known as==
*Code name: AL-3818
*Generic name: catequentinib
*Brand name: Fukewei
Category:Drugs
Category:Oral medications
Category:FGFR inhibitors
Category:VEGFR inhibitors
Category:Non-small cell lung cancer medications
Category:NMPA approved in 2018
Anti-inhibitor coagulant complex (FEIBA NF)

==Diseases for which is used==
*Inherited coagulopathy
==Also known as==
*Brand name: FEIBA NF
==References==
* Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zülfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011 Nov 3;365(18):1684-92. Erratum in: N Engl J Med. 2011 Dec 22;365(25):2441. link to original article EuroPMC
Category:Fractionated plasma products
Category:Intravenous medications
Category:Acquired coagulopathy medications
Category:FDA approved in 1986
Category:Stub
Antimicrobial prophylaxis

This is a stub page that will be expanded over time
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO/IDSA==
* 2018: Taplitz et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update EuroPMC
* 2018: Taplitz et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update EuroPMC
* 2013: Flowers et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline EuroPMC
Category:Supportive oncology
Antithrombin III, human (Thrombate III)

==General information==
Class/mechanism: Inhibitor of thrombin, which converts fibrinogen to fibrin in the coagulation cascade and subsequent development of thrombus. Clinical applications include management of patients with hereditary antithrombin III (AT-III) deficiency. Please choose from the products below to find specific drug/manufacturer information: 
*Antithrombin III, human (Thrombate III)Thrombate III manufacturer's websiteAntithrombin III, human (Thrombate III) package insert Antithrombin III, human (Thrombate III) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Patient drug information==
*Patient drug information (UpToDate)Patient drug information (UpToDate)
==History of changes in FDA indication==
*1991-12-30: Approved for replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.
==Also known as==
*Brand name: Thrombate III
==References==
Category:Fractionated plasma products
Category:Intravenous medications
Category:Inherited coagulopathy medications
Category:Hematology medications
Category:Coagulation factors
Category:FDA approved in 1991
Antithrombin III, recombinant (ATryn)

==General information==
Class/mechanism: Inhibitor of thrombin, which converts fibrinogen to fibrin in the coagulation cascade and subsequent development of thrombus. Clinical applications include management of patients with hereditary antithrombin III (AT-III) deficiency. Please choose from the products below to find specific drug/manufacturer information: 
*Antithrombin III, recombinant (ATryn)ATryn manufacturer's websiteAntithrombin III, recombinant (ATryn) package insert Antithrombin III, recombinant (ATryn) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Patient drug information==
*Patient drug information (UpToDate)Patient drug information (UpToDate)
*Brief patient counseling information can be found on page 15 of the ATryn package insert
==History of changes in FDA indication==
*2009-02-06: Initial approval for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
 
==Also known as==
*Brand name: ATryn
==References==
Category:Fractionated plasma products
Category:Intravenous medications
Category:Inherited coagulopathy medications
Category:Hematology medications
Category:Coagulation factors
Category:Recombinant medications
Category:FDA approved in 2009
Antithymocyte globulin, horse ATG (Atgam)

==General information==
Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.Antithymocyte globulin, horse ATG (Atgam) package insert Antithymocyte globulin, horse ATG (Atgam) package insert (locally hosted backup)Atgam manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Aplastic anemia
*Graft versus host disease
*Myelodysplastic syndrome
==Patient drug information==
*Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)
==History of changes in EMA indication==
*1981-11-17: EURD
==Also known as==
Note: different brands of horse ATG are likely to be from different host animals and will thus have different constituents; they should not be considered necessarily interchangeable.
*Brand names: Atgam, Lymphoglobuline, Thymogam
==References==
Category:Intravenous medications
Category:Fractionated plasma products
Category:Antithymocyte globulin
Category:Aplastic anemia medications
Category:Graft versus host disease medications
Category:Myelodysplastic syndrome medications
Category:EMA approved in 1981
Antithymocyte globulin, rabbit ATG (Grafalon)

This formulation of ATG is not FDA-approved in the United States, but is commonly used in Europe, the Middle East, and Asia.
==General information==
Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.Antithymocyte globulin, rabbit ATG (Grafalon) package insert> Antithymocyte globulin, rabbit ATG (Grafalon) package insert (locally hosted backup)Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18. link to original article EuroPMCKröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016 Jan 7;374(1):43-53. link to original article EuroPMC
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Aplastic anemia
*Graft versus host disease
*Myelodysplastic syndrome
==History of changes in EMA indication==
*1984-04-16: EURD
==Also known as==
*Generic names: anti-thymocyte globulin (rabbit), antithymocyte globulin (rabbit), lymphocyte immune globulin (rabbit)
*Brand names: ATG-Fresenius, Grafalon
==References==
Category:Fractionated plasma products
Category:Intravenous medications
Category:Antithymocyte globulin
Category:Aplastic anemia medications
Category:Myelodysplastic syndrome medications
Category:Graft versus host disease medications
Category:EMA approved in 1984
Antithymocyte globulin, rabbit ATG (Thymoglobulin)

==General information==
Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.Antithymocyte globulin, rabbit ATG (Thymoglobulin) package insert Antithymocyte globulin, rabbit ATG (Thymoglobulin) package insert (locally hosted backup)Thymoglobulin manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Aplastic anemia
*Graft versus host disease
*Myelodysplastic syndrome
==Patient drug information==
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) patient drug information (UpToDate)Antithymocyte globulin, rabbit ATG (Thymoglobulin) patient drug information (UpToDate)
==Also known as==
*Generic names: anti-thymocyte globulin (rabbit), antithymocyte globulin (rabbit), lymphocyte immune globulin (rabbit)
*Brand name: Imtix, Thymoglobulin
==References==
Category:Fractionated plasma products
Category:Intravenous medications
Category:Antithymocyte globulin
Category:Aplastic anemia medications
Category:Myelodysplastic syndrome medications
Category:Graft versus host disease medications
Apalutamide (Erleada)

==General information==
Class/mechanism: Antiandrogen; androgen receptor inhibitor (ARI). Apalutamide competitively inhibits activity mediated by the androgen receptor (AR) by binding directly to the AR ligand-binding domain, nuclear translocation, DNA binding, and AR-mediated transcription. A metabolite of apalutamide, 
N-desmethyl apalutamide, also exhibits some AR inhibiting activity, about 1/3 that of apalutamide.Apalutamide (Erleada) package insert Apalutamide (Erleada) package insert (locally hosted backup)Erleada manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Apalutamide (Erleada) package insert
*Apalutamide (Erleada) patient drug information (Chemocare)Apalutamide (Erleada) patient drug information (Chemocare)
*Apalutamide (Erleada) patient drug information (UpToDate)Apalutamide (Erleada) patient drug information (UpToDate)
==History of changes in FDA indication==
*2018-02-14: FDA approved for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). (Based on SPARTAN)
*2019-09-17: Approved for patients with metastatic castration-sensitive prostate cancer (mCSPC). (Based on TITANprostate)
==History of changes in EMA indication==
*2019-01-14: Initial marketing authorization as Erleada. Erleada is indicated in adult men for the treatment of non-metastatic castration resistant prostate cancer (NM CRPC) who are at high risk of developing metastatic disease. (Based on SPARTAN)
*2020-01-27: Extension of Indication to include the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). (Based on TITANprostate)
==History of changes in Health Canada indication==
*2018-07-03: Initial notice of compliance for the treatment of patients with non-metastatic castration-resistant prostate cancer at high risk of developing metastases.
*2019-12-12: New indication
==History of changes in PMDA indication==
*2019-03-26: New approval for the treatment of non-metastatic, castration-resistant prostate cancer.
*2020-05-29: New indication for the treatment of metastatic prostate cancer.
==Also known as==
*Code name: ARN-509
*Brand name: Erleada
==References==
Category:Drugs
Category:Oral medications
Category:Second-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:EMA approved in 2019
Category:FDA approved in 2018
Category:Health Canada approved in 2018
Category:PMDA approved in 2019
Apatinib (Aitan)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
==Diseases for which it is established (work in progress)==
*Hepatocellular carcinoma
==Diseases for which it is used==
*Esophageal cancer
**Esophageal adenocarcinoma
*Gastric cancer
*Non-small cell lung cancer, EGFR-mutated
*Thyroid cancer, differentiated
==Also known as==
*Code name: YN-968D1
*Generic name: rivoceranib
*Brand name: Aitan
Category:Drugs
Category:Oral medications
Category:VEGFR inhibitors
Category:KIT inhibitors
Category:SRC inhibitors
Category:Esophageal cancer medications
Category:Esophageal adenocarcinoma medications
Category:Gastric cancer medications
Category:Hepatocellular carcinoma medications
Category:Non-small cell lung cancer medications
Category:Thyroid cancer, differentiated medications
Category:NMPA approved drugs